Gland Pharma Q3 Profit Jumps 27.5%, Beats Estimates on Strong US, Europe Growth
Market
C
CNBC TV18•28-01-2026, 17:38
Gland Pharma Q3 Profit Jumps 27.5%, Beats Estimates on Strong US, Europe Growth
- •Gland Pharma reported a 27.5% year-on-year increase in net profit to ₹261.4 crore, surpassing market estimates.
- •Revenue grew by 22.5% to ₹1,695 crore, with EBITDA rising 20.8% to ₹434.9 crore, maintaining a stable EBITDA margin of 25.6%.
- •Performance was driven by disciplined execution, new product launches, and growth in base and CDMO businesses.
- •The company saw double-digit growth in the US and Europe, with Cenexi achieving breakeven.
- •Gland Pharma launched nine molecules and filed nine ANDAs in the US, increasing R&D spending to ₹65 crore.
Why It Matters: Gland Pharma exceeded Q3 profit and revenue estimates, fueled by strong US/Europe growth and strategic execution.
✦
More like this
Loading more articles...
